Bempegaldesleukin Boosts Responses in Melanoma.
Preliminary findings suggest that adding bempegaldesleukin to nivolumab may improve responses in patients with metastatic melanoma. In a phase I/II trial, the combination elicited responses in 20 out of 38 patients with newly diagnosed disease and was associated with relatively few side effects.